MGEN - Miragen Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.32
-0.02 (-0.27%)
At close: 4:00PM EDT

7.32 0.00 (0.00%)
After hours: 4:21PM EDT

Stock chart is not supported by your current browser
Previous Close7.34
Open7.33
Bid7.00 x 800
Ask8.50 x 1100
Day's Range7.08 - 7.38
52 Week Range5.01 - 15.91
Volume130,228
Avg. Volume158,876
Market Cap221.008M
Beta2.09
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.75
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201

    BOULDER, Colo., July 10, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the initiation of a Phase 2 clinical trial to evaluate MRG-201 in subjects with a predisposition for keloid formation. Subjects will receive small, matching excisional wounds that will be sutured and then injected with either MRG-201 or placebo.  Thus, patients will serve as their own control, which will increase the statistical powering of the trial.

  • Gaithersburg biotech raising $1M to stop cancer tumors in their tracks
    American City Business Journals13 days ago

    Gaithersburg biotech raising $1M to stop cancer tumors in their tracks

    Key story highlights: Gaithersburg-based miRecule Inc., which is developing therapeutics for cancers that become drug-resistant, is raising $1 million in seed funding. CEO Anthony Saleh spun the company out of the National Institutes of Health in 2016. Long term, Saleh plans to license its technology to pharmaceutical companies.

  • GlobeNewswirelast month

    Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting

    BOULDER, Colo., June 04, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced the first observations on the safety and efficacy of cobomarsen in adult T-cell leukemia/lymphoma (ATLL) patients, a highly morbid T-cell malignancy seen in patients previously infected with the human T-lymphotropic virus type 1 (HTLV1). The Company also released new interim data from its ongoing Phase 1 clinical trial of cobomarsen (also known as MRG-106), a microRNA-155 inhibitor, in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

  • GlobeNewswire2 months ago

    miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th

    BOULDER, Colo., May 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is scheduled to provide a company overview at the Jefferies 2018 Global Healthcare Conference at 10:00 am EDT on Thursday, June 7, 2018, at the Grand Hyatt Hotel in New York.

  • GlobeNewswire2 months ago

    miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting

    BOULDER, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim data from its ongoing Phase 1 clinical trial of cobomarsen (also known as MRG-106) in patients with the mycosis fungoides form of cutaneous T-cell lymphoma (CTCL) will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is being held June 1-5, 2018 in Chicago, IL.  In addition, preliminary observations on the safety and efficacy in adult T-cell leukemia/lymphoma (ATLL) patients dosed with cobomarsen will be presented. Cobomarsen is an inhibitor of microRNA-155.

  • GlobeNewswire2 months ago

    miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

    BOULDER, Colo., May 09, 2018 (GLOBE NEWSWIRE) --  miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported first quarter 2018 financial results and provided a corporate update. “With three product candidates now in clinical development and additional preclinical programs targeting multiple indications, we are continuing to advance, de-risk and build confidence in our pipeline of potential microRNA targeted therapies,” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics.

  • Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?
    Simply Wall St.2 months ago

    Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?

    In this commentary, I will examine Miragen Therapeutics Inc’s (NASDAQ:MGEN) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, asRead More...

  • GlobeNewswire2 months ago

    miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides

    BOULDER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new interim data from its Phase 1 clinical trial of cobomarsen in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). “These additional cobomarsen Phase 1 data provide further evidence that microRNA-based therapeutics have the potential to improve the quality of life for patients living with mycosis fungoides,” said miRagen President and CEO William S. Marshall, Ph.D. “Cobomarsen continues to be safe and generally well tolerated at all doses tested in the Phase 1 trial, with multiple patients receiving more than a year of therapy with no serious adverse events attributed to the drug.

  • GlobeNewswire2 months ago

    miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases

    BOULDER, Colo., May 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announces new data from two preclinical studies investigating microRNA mimics of the microRNA-183/96/182 cluster and MRG-201, a microRNA-29 mimic, to potentially treat ophthalmic diseases. Genetic analysis in animals and humans helped validate this microRNA cluster as a potential therapeutic target for retinal degeneration.

  • GlobeNewswire2 months ago

    miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018

    A replay of this conference call will be available on miRagen’s website approximately one hour after the event. MRG-110, an inhibitor of microRNA-92, is being developed under a license and collaboration agreement with Servier for the treatment of heart failure and other ischemic disease.

  • GlobeNewswire3 months ago

    miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110

    BOULDER, Colo., May 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the initiation of a second Phase 1 clinical trial of MRG-110 in collaboration with Servier.  MRG-110 is an inhibitor of microRNA-92.  In preclinical studies, MRG-110 accelerated the formation of new blood vessels, which resulted in improved perfusion of tissues and better functional outcomes in models of heart failure, peripheral artery disease and wound repair. “We are enthusiastic about the continued development of MRG-110, which is now advancing in two ongoing Phase 1 clinical trials,” said miRagen President and CEO William S. Marshall, Ph.D. “In preclinical studies, treatment with MRG-110 increased vascularization in a variety of different tissues.

  • GlobeNewswire3 months ago

    miRagen Therapeutics to Participate in Upcoming Investor Conferences

    BOULDER, Colo., April 30, 2018-- miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William ...

  • GlobeNewswire3 months ago

    miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings

    BOULDER, Colo., April 19, 2018-- miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it will ...

  • ACCESSWIRE4 months ago

    Blog Exposure - Foundation Medicine Collaborated with Chugai for Commercialization of FoundationOne CDx(TM) in Japan

    Stock Monitor: Miragen Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Foundation Medicine, Inc. (NASDAQ: ...

  • ACCESSWIRE4 months ago

    Miragen Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 14, 2018 / Miragen Therapeutics, Inc. (NASDAQ: MGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 14, 2018, at 4:30 PM Eastern ...

  • Benzinga6 months ago

    Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst

    Miragen Therapeutics, Inc. (NASDAQ: MGEN ), a development-stage biotech company, has product candidates for hematologic cancers and fibrotic diseases in its pipeline. The Analyst Oppenheimer analyst Leah ...

  • Where Miragen Therapeutics Inc (NASDAQ:MGEN) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.6 months ago

    Where Miragen Therapeutics Inc (NASDAQ:MGEN) Stands In Terms Of Earnings Growth Against Its Industry

    After looking at Miragen Therapeutics Inc’s (NASDAQ:MGEN) latest earnings update (30 September 2017), I found it helpful to revisit the company’s performance in the past couple of years and compareRead More...